Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18179683 | 0.89 | KMT2A (0.46) | KMT2AMEN1MAPTL3MBTL1HPGD | |
| SCHEMBL11152588 | 0.87 | TSHR (0.50) | KMT2AMEN1MAPTL3MBTL1HPGD | |
| SCHEMBL1374055 | 0.84 | TDP1 (0.51) | KMT2AMEN1MAPTL3MBTL1HPGD | |
| SCHEMBL1821139 | 0.83 | MAPT (0.45) | KMT2AMEN1MAPTL3MBTL1HPGD | |
| SCHEMBL8187564 | 0.82 | MAPT (0.56) | KMT2AMEN1MAPTL3MBTL1HPGD | |
| SCHEMBL6903596 | 0.80 | CA12 (0.56) | KMT2AMEN1MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL1376927 | 0.79 | SMN1; SMN2 (0.44) | KMT2AMEN1MAPTL3MBTL1TDP1 | |
| SCHEMBL11412681 | 0.79 | CA1 (0.53) | L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL5313540 | 0.79 | USP5 (0.49) | KMT2AL3MBTL1HPGDALDH1A1LMNA | |
| SCHEMBL4686898 | 0.79 | LMNA (0.61) | KMT2AMEN1MAPTL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | HONGU MITSUYA | 2010-10-07 | — | — | US | disclosed |
| US-7759373-B2 | Large conductance calcium-activated K channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20040127527-A1 | Large conductance calcium-activated k channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | KCNN3, KCNN2, KCNN1 | KMT2A 1947/4885MEN1 2380/4885MAPT 2752/4885 |
| US-20040127527-A1 | Large conductance calcium-activated k channel opener | KCNN1, KCNN4, KCNN3 | KMT2A 2017/4885MEN1 3427/4885MAPT 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.